Records containing: Neovascular Age-related Macular Degeneration
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2022-03-09Home OCT Fluid Visualization Agreement Study at Multiple Retinal Clinics With Placement of One Home OCT Device in the Home of Each NV-AMD Subject in the US for 5 Weeks
-
CLINICAL_TRIALS study record update · 2022-02-02A Phase 2A Open-label Trial to Assess the Safety of ZIMURA™ (Anti-C5) Administered in Combination With LUCENTIS® 0.5 mg in Treatment Naive Subjects With Neovascular Age Related Macular Degeneration
-
CLINICAL_TRIALS study record update · 2022-01-20A Phase I Clinical Study of ALT-L9 in Patients With Neovascular Age-related Macular Degeneration
-
CLINICAL_TRIALS study record update · 2021-12-29Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept
-
CLINICAL_TRIALS study record update · 2021-12-23Evaluation of Repeated, In-Clinic, Self-Imaging by NV-AMD Patients Using the Notal Vision Home OCT
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2021-11-11A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of IBI302 in Patients With Neovascular Age-related Macular Degeneration (nAMD)
-
CLINICAL_TRIALS study record update · 2021-11-09Adjunctive Photodynamic Therapy for Persistent Disease Activity in Patients With Neovascular Age-Related Macular Degeneration
-
CLINICAL_TRIALS study record update · 2021-06-24A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-1)
-
CLINICAL_TRIALS study record update · 2021-06-23A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-2)
-
CLINICAL_TRIALS study record update · 2021-04-27A Double-center, Open-label,Single Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intravitreous Injections of RC28-E (a Chimeric Decoy Receptor Trap Fusion Protein by Dual Blockage of VEGF and FGF-2) in Subjects With Wet Age-Related Macular Degeneration
-
CLINICAL_TRIALS study record update · 2021-04-27Time Efficiency Comparison of Two Intravitreal Injection Techniques
-
CLINICAL_TRIALS study record update · 2021-01-12A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
-
CLINICAL_TRIALS study record update · 2020-12-19A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
-
CLINICAL_TRIALS study record update · 2020-11-04A Phase I/II, Single-center, Randomized Double Masked Placebo Controlled Study to Evaluate the Safety and Efficacy of Treatment With AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)
-
CLINICAL_TRIALS study record update · 2020-09-16An 18-Month Phase Ib/II Multi-Center, Open Label Study to Evaluate the Safety of Intravitreal APL-2 Therapy in Patients With Neovascular Age-Related Macular Degeneration (AMD)
-
CLINICAL_TRIALS study record update · 2020-06-19A Randomized Controlled Trial Comparing the Effect of Topical Dorzolamide-Timolol Versus Placebo Combined With Intravitreal Anti-Vascular Endothelial Growth Factor (VEGF) Injections in Patients With Neovascular Age-Related Macular Degeneration Who Are Incomplete Anti-VEGF Responders
-
CLINICAL_TRIALS study record update · 2020-04-30A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
-
CLINICAL_TRIALS study record update · 2020-02-19Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration
-
CLINICAL_TRIALS study record update · 2019-12-16Timing of Low Vision Rehabilitation in Anti-VEGF Therapy: a Randomized, Controlled Trial
-
CLINICAL_TRIALS study record update · 2019-10-01A Cross Sectional Study Assessing the Perifoveal and Peripapillar Vessel Density in nAMD After Longterm Anti-VEGF Treatment Compared to Recently Started Anti-VEGF Treatment - Pilotstudy
-
CLINICAL_TRIALS study record update · 2019-08-20Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration.
-
CLINICAL_TRIALS study record update · 2019-07-09A Randomized, Double Masked, Uncontrolled , Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Naïve Participants With Neovascular Age-Related Macular Degeneration (AMD)
-
CLINICAL_TRIALS study record update · 2019-04-17Pain Control Following Intravitreal Injection Using Topical Nepefanac 0.3% or Pressure Patching: A Prospective, Randomized, Placebo Controlled Trial
-
CLINICAL_TRIALS study record update · 2019-03-21A 12-month, Phase IV, Randomized, Open Label, Multicenter Study to Compare Efficacy of 0.5 mg Ranibizumab Pro re Nata (PRN) Versus 2 mg Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability Till Month 6 of Treatment and Explore Functional Outcomes up to Month 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD)
-
CLINICAL_TRIALS study record update · 2019-02-15A Phase IV, Prospective, Open-label, Uncontrolled, European Study in Patients With Neovascular Age-related Macular Degeneration (nAMD), Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to Ranibizumab 0.5mg.